A strategy employed in this study was to substitute paracrine contribution from melanoma stroma with exogenous bFGF, EGF and HGF, provided either alone or in combination in the culture medium, and then extensively investigate the possible alteration in melanoma cell phenotype and cell response to vemurafenib and trametinib. The gene discussed is FGF2; the disease is melanoma.